CinCor Pharma

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor.

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CinCor Pharma, Inc. (NasdaqGM: CINC) to AstraZeneca. Under the terms of the proposed transaction, shareholders of CinCor will receive $26.00 in cash plus a non-tradable contingent value right of $10.00 (payable upon a specified regulatory submission of a baxdrostat product) for each share of CinCor that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

Albireo Pharma

There's nothing like a big-premium buyout to send a company's share price to the moon.

Why These Two Biotech Stocks Blasted Higher This Week

CINCOR PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

AstraZeneca

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed acquisition of the Company by AstraZeneca PLC (NASDAQ: AZN) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $26.00 in cash for each share of CinCor common stock owned, plus a non-tradable contingent value right ("CVR") of $10.00.

SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating CinCor Pharma, Inc. (NASDAQ: CINC), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, CINC shareholders are expected to receive $26.00 and one Contingent Value Right worth $10.00 in cash per share they own.

EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of CinCor Pharma, Inc - CINC

Wilmington, Delaware--(Newsfile Corp. - January 9, 2023) - Rigrodsky Law, P.A. is investigating CinCor Pharma, Inc. ("CinCor") (NASDAQ GM: CINC) regarding possible breaches of fiduciary duties and other violations of law related to CinCor's agreement to be acquired by AstraZeneca PLC. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cincor-pharma-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CinCor Pharma, Inc. Buyout

CinCor Pharma (CINC) announced that it has entered into a definitive agreement with AstraZeneca (AZN) under which AstraZeneca has agreed to acquire CinCor. These are the details.

Why AstraZeneca Is Buying CinCor Pharma For $1.8 Billion (AZN) (CINC)

MILWAUKEE , Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating CinCor (Nasdaq: CINC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.  Click here to learn how to join the action https://www.ademilaw.com/case/cincor-pharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether CinCor Pharma, Inc. has obtained a Fair Price in its transaction with AstraZeneca

AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion. The post AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal appeared first on Investor's Business Daily.

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.

Why Is CinCor (CINC) Stock Up 138% Today?

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CinCor Pharma, Inc. (NASDAQ: CINC) to AstraZeneca for $26.00 per share in cash at closing, plus a non-tradable contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product, is fair to CinCor shareholders.

CINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CinCor Pharma, Inc. Is Fair to Shareholders

AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued at US$522mln late September.

AstraZeneca to acquire CinCor for US$1.8bn

AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline

AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal

For an initial $1.3 billion, the Anglo-Swedish company will acquire CinCor Pharma, including rights to its baxdrostat cardiorenal drug, which has shown promise in clinical trials.

AstraZeneca to Buy U.S. Cardiorenal-Drug Maker

AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug for an upfront transaction value of around $1.3 billion.

AstraZeneca will buy U.S.-based CinCor for cardiorenal asset

AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal

WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.

CinCor Pharma to be Acquired by AstraZeneca

Bandwidth

4D Molecular Therapeutics

GrowGeneration Corp

Imago Biosciences

Nutex Health Inc

Silvergate Capital Corp

Vacasa

Veru

Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.

These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022

CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.

CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug

Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat.

CinCor's hypertension drug misses primary endpoint in mid-stage study

Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP)

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences

Arcellx

Amylyx Pharmaceuticals

Belite Bio Inc

Credo Technology Group Holding Ltd

Golden Sun Education Group Ltd

AMTD Digital

Mobileye Global Inc

Nuvectis Pharma

The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.

These Are the 10 Best-Performing IPOs in 2022 Through October

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom. The presentation information is below:

News for CinCor Pharma Stock (CINC)